Buckeye Partners, L.P. owns and operates liquid petroleum products pipelines in the United States. The company has market cap of $7.15 billion. The firm operates through three divisions: Domestic Pipelines & Terminals, Global Marine Terminals, and Merchant Services. It has a 14.67 P/E ratio. The Domestic Pipelines & Terminals segment transports liquid petroleum products, including gasoline, jet fuel, diesel fuel, heating oil, and kerosene; refined petroleum products, such as propane and butane, refinery feedstock, and blending components; and crude oil.
Analysts expect Tesaro, Inc. (NASDAQ:TSRO) to report $-2.41 EPS on February, 27 after the close.They anticipate $0.19 EPS change or 7.31% from last quarter’s $-2.6 EPS. After having $-0.47 EPS previously, Tesaro, Inc.’s analysts see 412.77% EPS growth. The stock increased 3.83% or $2.3 during the last trading session, reaching $62.3. About 1.06M shares traded or 4.88% up from the average. Tesaro, Inc. (NASDAQ:TSRO) has risen 254.28% since February 21, 2017 and is uptrending. It has outperformed by 237.58% the S&P500.
Analysts await Buckeye Partners, L.P. (NYSE:BPL) to report earnings on May, 4. They expect $0.82 earnings per share, down 6.82% or $0.06 from last year’s $0.88 per share. BPL’s profit will be $120.28 million for 14.85 P/E if the $0.82 EPS becomes a reality. After $0.85 actual earnings per share reported by Buckeye Partners, L.P. for the previous quarter, Wall Street now forecasts -3.53% negative EPS growth.
The stock increased 0.66% or $0.32 during the last trading session, reaching $48.71. About 464,206 shares traded. Buckeye Partners, L.P. (BPL) has declined 5.99% since February 21, 2017 and is downtrending. It has underperformed by 22.69% the S&P500.
Trust Asset Management Llc holds 5.04% of its portfolio in Buckeye Partners, L.P. for 242,822 shares. Center Coast Capital Advisors Lp owns 3.48 million shares or 4.92% of their US portfolio. Moreover, C.V. Starr & Co. Inc. Trust has 4.75% invested in the company for 180,000 shares. The Colorado-based Alps Advisors Inc has invested 4.63% in the stock. Eagle Global Advisors Llc, a Texas-based fund reported 2.59 million shares.
Ratings analysis reveals 25% of Buckeye Partners’s analysts are positive. Out of 4 Wall Street analysts rating Buckeye Partners, 1 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. The lowest target is $73.0 while the high is $78.0. The stock’s average target of $76.25 is 56.54% above today’s ($48.71) share price. BPL was included in 4 notes of analysts from August 25, 2016. The firm has “Buy” rating given on Wednesday, October 26 by Stifel Nicolaus. Credit Suisse initiated Buckeye Partners, L.P. (NYSE:BPL) on Wednesday, October 12 with “Neutral” rating. As per Thursday, August 25, the company rating was initiated by Goldman Sachs. Mizuho initiated the stock with “Neutral” rating in Friday, September 30 report.
Among 25 analysts covering Tesaro Inc (NASDAQ:TSRO), 14 have Buy rating, 1 Sell and 10 Hold. Therefore 56% are positive. Tesaro Inc had 65 analyst reports since August 24, 2015 according to SRatingsIntel. The firm earned “Outperform” rating on Friday, August 18 by Credit Suisse. The company was maintained on Monday, October 10 by FBR Capital. The firm has “Buy” rating given on Thursday, July 27 by Oppenheimer. The stock of Tesaro, Inc. (NASDAQ:TSRO) has “Buy” rating given on Friday, August 5 by Mizuho. Cowen & Co maintained it with “Hold” rating and $14500 target in Monday, June 5 report. The stock of Tesaro, Inc. (NASDAQ:TSRO) has “Hold” rating given on Wednesday, September 6 by Cowen & Co. Robert W. Baird initiated the stock with “Outperform” rating in Tuesday, July 19 report. The stock has “Outperform” rating by Leerink Swann on Monday, October 10. The firm earned “Buy” rating on Tuesday, August 8 by Oppenheimer. The rating was maintained by Wedbush with “Outperform” on Monday, October 10.
Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. The company has market cap of $3.39 billion. It markets Rolapitant, a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting under the VARUBI brand name. It currently has negative earnings. The firm is also developing Niraparib, an orally active and potent poly polymerase inhibitor, which is in various clinical trials to treat ovarian or breast cancers.
Since September 1, 2017, it had 0 insider buys, and 5 sales for $4.63 million activity. 10,862 shares were sold by English Edward C, worth $1.47M on Wednesday, September 6. Shares for $70,211 were sold by Huber Martin H. Jr. on Thursday, September 21. The insider Oliveira Orlando sold $9,419. Another trade for 14,167 shares valued at $1.91M was made by Bogle Grant C. on Friday, September 1. Armitage James O had sold 10,000 shares worth $1.17 million.
Investors sentiment decreased to 1.21 in 2017 Q3. Its down 0.25, from 1.46 in 2017Q2. It fall, as 47 investors sold Tesaro, Inc. shares while 65 reduced holdings. 44 funds opened positions while 91 raised stakes. 58.28 million shares or 5.16% more from 55.42 million shares in 2017Q2 were reported. Jpmorgan Chase & has invested 0% in Tesaro, Inc. (NASDAQ:TSRO). Geode Capital Management Ltd Co reported 336,325 shares. Camber Cap Mgmt Ltd stated it has 400,000 shares or 3.27% of all its holdings. Advisory Svcs Network Ltd Liability reported 14 shares. Oregon Pub Employees Retirement Fund holds 0.02% or 7,351 shares in its portfolio. Nuveen Asset Ltd Llc holds 0.04% or 52,834 shares. Hsbc Hldg Public Limited Company accumulated 13,383 shares. Bnp Paribas Asset Sa accumulated 0.09% or 85,984 shares. Glg Ltd Llc reported 22,563 shares stake. Parametric Port Assocs Ltd Co reported 29,633 shares. Weiss Multi accumulated 45,000 shares. 1,696 are owned by Envestnet Asset Mgmt. Sei invested in 0.01% or 13,162 shares. Bluestein R H & has 3,000 shares. Ubs Asset Management Americas has invested 0.04% of its portfolio in Tesaro, Inc. (NASDAQ:TSRO).